Modulation of growth factor action: Implications for the treatment of cardiovascular diseases

Circulation

Volumn 96, Issue 11, 1997, Pages 4083-4094

  Waltenberger, Johaones ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Atherosclerosis; Collateral circulation; Growth substances

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANGIOPLASTY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL CYCLE; EXTRACELLULAR MATRIX; GENE TRANSFER; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RECOMBINANT DNA TECHNOLOGY; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030695252     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.11.4083     Document Type: Review

References (156)

1. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809-813.
2. Sporn MB, Roberts AB. Autocrine growth factors and cancer, Nature. 1985;313:745-747.
3. Kovalenko M, Gazit A, Böhmer A, Rorsman C, Heldin C-H, Waltenberger J, Böhmer F-D, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sistransformation. Cancer Res. 1994;54:6106-6114.
4. Vassbotn FS, Andersseon M, Westermark B, Heldin C-H, Östman A. Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol. 1993;13: 4066-4076.
5. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastotma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994;367:576-579.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
7. Schaper W, Schaper J, eds. Collateral Circulation: Heart, Brain, Kidney, Limbs. Boston/Dordrecht/London: Kluwer Academic Publishers; 1993.
8. Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res. 1996;79:911-919.
9. Claesson-Welsh L. Mechanism of action of platelet-derived growth factor. Int J Biochem Cell Biol. 1996;28:373-385.
10. Nasmyth K. Viewpoint: Putting the cell cycle in order. Science, 1996;274:1643-1645.
11. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
12. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor p21 Inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest, 1995;96:2260-2268.
13. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 1996;381:713-716.
14. Kipl display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707-720.
15. ten Dijke P, Miyazono K, Heldin C-H. Signaling via heterooligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol. 1996;8:139-145.
16. Hill CS. Signalling to the nucleus by members of the transforming growth factor-β (TGF-β) superfamily. Celt Signal. 1996;8:533-544.
17. Heldin C-H. Structural and functional studies on platelet-derived growth factor. EMBO J. 1992;11:4251-4259.
18. Raines EW, Bowen-Pope DF, Ross R. Platelet-derived growth factor. In: Sporn MB, Roberts AB, eds. Handbook of Experimental Pharmacology: Peptide Growth Factors and Their Receptors. Heidelberg: Springer-Verlag; 1990:173-262.
19. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994;93:1266-1274.
20. Calara F, Ameli S, Hultgårdh-Nilsson A, Cercek B, Kupfer J, Hedin U, Forrester J, Shah PK, Nilsson J. Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells: potential role of FGF and PDGF. Arterioscler Thromb Vasc Biol. 1996;16:187-193.
21. Lindner V, Reidy MA. Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo. Am J Pathol. 1995;146:1488-1497.
22. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
23. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC, Nabel GJ. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest, 1993;91:1822-1829.
24. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253: 1129-1132.
25. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGFR-β receptor subunit expression directs suppression of intimal thickening. Circulation. 1997;95:669-676.
26. Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123:1439-1444.
27. Ohnishi H, Yamaguchi K, Shimada S, Suzuki Y, Kumagai A. A new approach to the treatment of atherosclerosis and trapidil as an antagonist to platelet-derived growth factor. Life Sci. 1981;28: 1641-1645
28. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest. 1992;89:465-473.
29. Fox JC, Shanley JR. Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. J Biol Chem. 1996;271:12578-12584.
30. Schwartz SM, Bennett MR. Death by any other name. Am J Pathol. 1995;147:229-234.
31. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β), Growth Factors. 1993;8:1-9.
32. Waltenberger J, Lundin L, Öberg K, Wilander E, Miyazono K, Heldin C-H, Funa K. Involvement of transforming growth factor-β in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol. 1993;142:71-78.
33. Waltenberger J, Wanders A, Fellström B, Miyazono K, Heldin C-H, Funa K. Induction of transforming growth factor-β during cardiac allograft rejection. J Immunol. 1993;151:1147-1157.
34. Waltenberger J, Akyürek ML, Aurivillius M, Wanders A, Larsson E, Fellström B, Funa K. Ischemia-induced transplant arteriosclerosis in the rat: induction of peptide growth factor expression. Arterioscler Thromb Vasc Biol. 1996;16:1516-1523.
35. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid protein A in severe unstable angina. N Engl J Med. 1994;331:417-424.
36. Grainger DJ, Kirschenlohr HL, Metcalfc JC, Weissberg PL, Wade DP, Lawn RM. Atherogenic lipoprotein(a) promotes the proliferation of human smooth muscle cells. Science. 1993;260:1655-1658.
37. Koh GY, Kim S-J, Klug MG, Park K, Soonpaa MH, Field LJ. Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest. 1995;95:114-121.
38. Nabel EG, Skum L, Pompili VJ, Yang Z-Y, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759-10763.
39. Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, Oohashi H, Kasayuki N, Ueda M, Morisaki N. In vivo effect of TGF-β1: enhanced intimal thickening by administration of TGF-β1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol. 1995;15:1951-1957.
40. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest. 1994;93:1172-1178.
41. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996;271:603-606.
42. a. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G. VEGF(145), a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem. 1997;272:7151-7158.
43. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A. 1996;93:2576-2581.
44. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the FH4 (VEGFR-3) and (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298.
45. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
46. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res. 1994;28:1176-1179.
47. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 1995;270:19761-19766.
48. Waltenberger J, Claesson-Welsh L, Sieghahn A, Shibuya M, Heldin C-H. Different signal transductiun properties of KDR and F, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269:26988-26995.
49. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. J Clin Invest. 1995;95:1798-1807.
50. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular eodothelial growth factor receptor KDR by hypoxia. Circulation. 1996;94:1647-1654.
51. Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor FLT-1 mediates biological activities: implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271:17629-17634.
52. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu L-Q, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single iniraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93:662-670.
53. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994;89:2183-2189.
54. Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladstone SR, Friedman M, Sellke FW, Simons M. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med. 1995;1:1085-1089.
55. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, Simons M. Vascular endothelial growth factor administration in chronic myorardial ischemia. Am J Physiol. 1996;270:H1791-H1802.
56. Engler DA. Use of vascular endothelial growth factor for therapeutic angiogenesis. Circulation. 1996;94:1496-1498.
57. Callow AD, Choi ET, Trachtenberg JD, Stevens SL, Connolly DT, Rodi C, Ryan US. Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty. Growth Factors. 1994;10:223-228.
58. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara M, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91:2793-2801.
59. Merenmies J, Parada LF, Henkenmeyer M. Receptor tyrosine kinase signaling in vascular development. Cell Growth Differ. 1997;8:3-10.
60. a. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
61. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171-1180.
62. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries: an en face study. Circ Res. 1993;73:589-595.
63. Folkman J, Shing Y, Angiogenesis. J Biol Chem. 1992;267:10931-10934.
64. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, Sugimoto T, Kaji K, Utsuyama M, Kurashima C, Ito H. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 1992;257:1401-1403.
65. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg. 1992;16:181-191.
66. Chlebourn JO, Martins RN, Mitchell CA, Chirila TV. bFGF enhances the development of the collateral circulation after acute arterial occlusion, Biochem Biophys Res Commun. 1992;185:510-516.
67. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, DiSegni E, Varda-Bloom N, Nass D, Engelberg S, Eldar M, Belkin M, Savion N. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol. 1993;22:2001-2006.
68. Harada K, Grossman W, Friedman M, Edelman ER, Prasad PV, Keighley CS, Manning WJ, Sellke FW, Simons M. Basic flbroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest. 1994;94:623-630.
69. Uchida Y, Yanagisawa-Miwa A, Ikuta M, Makamura F, Tomaru T, Fujimori Y, Morita T. Angiogenic therapy of acute myocardial infarction (AMI) by intrapericardial injection of basic fibroblast growth factor (bFGF) and haparan sulfate (HS): an experimental study. Circulation. 1994;90(suppl I):I-296. Abstract.
70. Unger EF, Banai S, Shou M, Lazarous DF, Jaklitseh MT, Scheinowitz M, Correa R, Klingbeil C, Epstein SE. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol. 1994;35:H1588-H1595.
71. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam MAS, Hunsberger S, Robinson G Jr, Stiber JA, Correa R, Epstein SE, Unger EF. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation. 1995;91:145-153.
72. Barrios V, Cuevas B, Carceller F, Asin E, Jiménez JJ, Navarro J, Garcia-Segovia J, Moya JL, Minguez I, Cuevas P. Angiogenesis in the rat heart induced by local, delivery of basic fibroblast growth factor. Ear Heart J. 1995;16(suppl):171. Abstract.
73. Yang HT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ Res. 1996;79:62-69.
74. Horrigan MCG, MacIsaac AI, Nicolini FA, Vince DG, Lee P, Ellis SG, Topol EJ. Reduction of myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation. 1996;94:1927-1933.
75. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond K. Intracoronary gene transfer of fibrobtast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996;2:534-539.
76. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189:824-831.
77. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation. 1995;92:11-14.
78. Lindner Y, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68:106-113.
79. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996;94:1074-1082.
80. Martins RN, Chleboun JO, Sellers P, Sleigh M, Muir J. The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion. Growth Factors. 1994;10:299-306.
81. Brown DM, Hong SP, Farrell CL, Pierce GF, Khouri RK. Platelet-derived growth factor BB induces functional vascular anastomoses in vivo, Proc Natl Acad Sci U S A. 1995;92:5920-5924.
82. Hermansson M, Nistér M, Betsholtz C, Heldin C-H, Westermark B, Funa K. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A. 1988;85:7748-7752.
83. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, Heldin C-H. Platelet-derived growth factor is angiogenic in vivo. Growth Factory. 1992;7:261-266.
84. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652.
85. Landgren E, Eriksson A, Wennström S, Kanda S, Claesson-Welsh L. Induction of fibroblast growth factor receptor-1 mRNA and protein by platelet-derived growth factor BB. Exp Cell Res. 1996;223:405-411.
86. Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Ylä-Herttuala S, Risau W, Martin JF, Erusalimsky JD. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression, of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 1995;358:311-315.
87. O'Brian ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145:883-894.
88. Ferrara N, Winer J, Button T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors. 1991;5:141-148.
89. Nabel EG, Yang Z-Y, Piautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ, Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature. 1993;362:844-846.
90. Sioussat TM, Dvorak HF, Brock TA, Senger DR. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys. 1993;301:15-20.
91. Vassbotn FS, Östman A, Siegbahn A, Holmsen H, Heldin C-H. Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGF α- and β-receptor signals in cells expressing both receptor types. J Biol Chem. 1992;267:15635-15641.
92. Engström U, Engström Å, Ernlund A, Westermark B, Heldin C-H. Identification of a peptide antagonist for platelet-derived growth factor. J Biol Chem. 1992;267:16581-16587.
93. Benezra M, Ben-Sasson SA, Regan J, Chang M, Bar-Shavit R, Vlodavsky I. Antiproliferative activity to vascular smooth muscle cells and receptor binding of heparin-mimicking polyaromatic anionic compounds. Arterioscler Thromb. 1994;14:1992-1999.
94. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem. 1985;29:265-273.
95. Braddock PS, Hu D-E, Fan T-PD, Stratford IJ, Harris AL, Bicknell R. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer. 1993;69:890-898.
96. Waltenberger J, Mayr U, Frank H, Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor; a contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 1996;28:1523-1529.
97. Gagliardi A, Hadd H, Collins DC. Inhibition of angiogenesis by suramin. Cancer Res. 1992;52:5073-5075.
98. Asada Y, Tsuneyoshi A, Marutsuka K, Sumiyoshi A. Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo. Cardiovasc Res. 1994;28:1166-1169.
99. Mullins DE, Hamud F, Reim R, Davis HR. Inhibition of PDGF receptor binding and PDGF-stimulated biological activity in vitro and of intimal lesion formation in vivo by 2-bromomethyl-5-chlorobenzene sulfonylphthalimide. Arterioscler Thromb. 1994;14:1047-1055.
100. Jellinek D, Green LS, Bell C, Janjic N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothetial growth factor. Biochemistry. 1994;33:10450-10456.
101. Green LS, Jellinek D, Jenison R, Östman A, Heldin C-H, Janjic N. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry. 1996;35:14413-14424.
102. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267:1782-1788.
103. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB. Selective inhibition of platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A. 1995;92:2558-2562.
104. Gazit A, App H, McMahon G, Chen J, Levitzki A, Böhmer FD. Tyrphostins, 5: potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem. 1996;39:2170-2177.
105. Ito A, Shimokawa H, Kadokami T, Fukumoto Y, Owada MK, Shiraishi T, Nakaike R, Takayanagi T, Egashira K, Takeshita A. Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1β in pigs in vivo. J Clin Invest. 1995;96:1288-1294.
106. Ueno H, Colbert H, Escobedo JA, Williams LT. Inhibition of PDGF β receptor signal transduction by coexpression of a truncated receptor. Science. 1991;252:844-848.
107. Yamamoto H, Ueno H, Ooshima A, Takeshita A. Adenovirus-mediated transfer of a truncated transforming growth factor-β (TGF-β) type II receptor completely and specifically abolishes diverse signaling by TGF-β in vascular wall cells in primary culture. J Biol Chem. 1996;271:16253-16259.
108. Duan D-SR, Pazin MJ, Fretto LJ, Williams LT. A functional soluble extracellular region of the platelet-derived growth factor (PDGF) β-receptor antagonizes PDGF-stimulated responses. J Biol Chem. 1991;266:413-418.
109. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90:10705-10709.
110. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226:324-328.
111. Schweitzer R, Howes R, Smith R, Shilo B-Z, Freeman M. Inhibition of Drosophila EGF receptor activation by the secreted protein Argos. Nature. 1995;376:699-702.
112. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, Froehlich JP, Crow MT, Lakatta EG, Rowinsky EK, Kinsella JL. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95:1869-1876.
113. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science. 1993;261:1004-1012.
114. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994;372:333-335.
115. Behl C, Bogdahn U, Winkler J, Apfel R, Brysch W, Schlingensiepen KH. Autoinduction of platelet derived growth factor (PDGF) A-chain mRNA expression in a human malignant melanoma cell line and growth inhibitory effects of PDGF-A-chain mRNA-specific antisense molecules. Biochem Biophys Res Commun. 1993;193:744-751.
116. Liu M, Liu J, Buch S, Tanswell AK, Post M, Antisense oligonucleotides for PDGF-B and its receptor inhibit mechanical strain-induced fetal lung cell growth. Am J Physiol. 1995;269:L178-L184.
117. Cheng S-Y, Huang H-JS, Nagane M, Ji X-D, Wang D, Shih CC-Y, Arap W, Huang C-M, Cavenee WK. Suppression of glioblastoma and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 1996;93:8502-8507.
118. Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
119. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian Y-X, Bayewitch LA, Cohen AM, Herrara CJ, Hu SS-F, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL, The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A. 1995;92:4051-4055.
120. Casscells W, Lappi DA, Olwin BB, Wai C, Siegman M, Speir EH, Sasse J, Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc Natl Acad Sci U S A. 1992;89:7159-7163.
121. Epstein SE, Siegall CB, Brio S, Fu Y-M, FitzGerald D, Pastan I. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation. 1991;84:778-787.
122. Chen C, Mattar SG, Hughes JD, Pierce GF, Cook JE, Ku DN, Hanson SR, Lumsden AB. Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft. Circulation. 1996;94:1989-1995.
123. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angtogenesis in vivo. Cancer Res. 1996;56:1324-1330.
124. Lundergan C, Foegh ML, Vargas R, Eufemio M, Bormes GW, Kot PA, Ramwell PW. Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034. Atherosclerosis. 1989;80:49-55.
125. Wanders A, Akyürek ML, Waltenberger J, Stafberg C, Larsson E, Zhiping R, Funa K, Fellström B. Impact of ischemia time on chronic vascular rejection in the rat - effects of angiopeptin, Transplant Proc. 1993;25:2098-2099.
126. von Scheidt W, Meiser BM, Gross T, Mair H, Koglin J, Überfuhr P, Foegh M, Reichart B, Steinbeck G. Angiopeptin inhibits coronary intimal proliferation after human cardiac transplantation. Eur Heart J. 1995;16(suppl):274. Abstract.
127. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature. 1992;360:361-364.
128. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg. 1995;21:314-325.
129. Nabel EG. Gene therapy for cardiovascular disease. Circulation. 1995;91:541-548.
130. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stems with genetically engineered endothelial cells. Circulation. 1989;80:1347-1353.
131. Roemer K, Friedmann T. Concepts and strategies for human gene therapy. Eur J Biochem. 1992;208:211-225.
132. Mühlhauser J, Merrill MJ, Pili R, Maeda H, Bacic M, Bewig B, Passaniti A, Edwards NA, Crystal RG, Capogrossi MC. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res. 1995;77:1077-1086.
133. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79.
134. Stein B, Fuster V. Clinical pharmacology of platelet inhibitors. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders; 1992:99-120.
135. Grainger DL, Weissberg PL, Metcalfe JC, Tamoxifen decreases the rate of proliferation of rat vascular smooth muscle cells in culture by inducing the production of transforming growth factor-β. Biochem J. 1993;294:109-112.
136. Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced for mation of lipid lesions in mouse aorta. Nat Med. 1995;1:1067-1073.
137. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, Rossow S, Rosenfield K, Weir L, Brogi E, Schainfeld R. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation. 1995;91:2687-2692.
138. 165 in patient with ischacmic limb. Lancet. 1996;348:370-374.
139. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, Horowitz JR, Symes JF, Isner JM. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation. 1996;94:3281-3290.
140. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Inducing the formation of new blood vessels: a novel approach to treating myocardial ischemia. Nat Med. 1997;3:2.
141. Stein CA. Does antisense exist? Nat Med. 1995;11:1119-1121.
142. Villa AE, Guzman LA, Poptic EJ, Labhasetwar V, D'Souza S, Farrell CL, Plow EF, Levy RJ, DiCorleto PE, Topol EJ. Effect of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res. 1995;76:505-513.
143. Guvakova MA, Yakubov LA, Vlodavsky L, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it: from low affinity binding sites on extra-cellular matrix. J Biol Chem. 1995;270:2620-2627.
144. Chester KA, Hawkins RE. Clinical issues in antibody design. Trends Biotechnol. 1995;13:294-300.
145. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995;96:2955-2965.
146. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation. 1995;91:2407-2414.
147. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips HS, Terrell T, Keller GA, Levinson AD. Expression of vascular endothelial growth factor does not promote transformation hut confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest. 1993;91:160-170.
148. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: fact, fancy and future. Circulation. 1994;90:2070.
149. Serruys PW. BENESTENT-U pilot study: 6 month follow-up of phase 1, 2 and 3. Circulation, 1995;92(suppl I):I-542-I-543.
150. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.
151. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem. 1994;269:6271-6274.
152. Mandriota SJ, Menoud P-A, Pepper MS. Transforming growth factor β1 down-regulates vascular endothelial growth factor receptor 2/flk-l expression in vascular endothelial cells. J Biol Chem. 1996;271:11500-11505.
153. Paulsson Y, Beckmann MP, Westermark B, Heldin C-H. Density-dependent Inhibition of cell growth by transforming growth factor-β1 in normal human fibroblasts. Growth factors. 1988;1:19-27.
154. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by C-myc antisense oligonucleotides. J Clin Invest. 1994;93:820-828.
155. Abe J-I, Zhou W, Taguchi J-I, Takuwa N, Miki K, Okazaki H, Kurokawa K, Kumada M, Takuwa Y. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun. 1994;198:16-24.
156. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8478.